Kailera executive reports stock option holdings
Kailera Therapeutics, Inc. executive Paul D. Burgess filed an initial ownership report showing three direct stock option positions in the company’s common stock.
Rhea-AI Filing Summary
Kailera Therapeutics, Inc. executive Paul D. Burgess filed an initial ownership report showing three direct stock option positions in the company’s common stock. These options give rights to acquire 325,491 shares at an exercise price of $7.24, and 191,444 and 285,307 shares each at $5.25 per share.
The options tied to 285,307 shares vested 25% on December 9, 2025, with the rest in 36 monthly installments, while those for 191,444 shares vested 25% on September 16, 2025 on a similar schedule. The 325,491‑share grant is scheduled to vest 25% on November 5, 2026, then in 36 monthly installments, all subject to Burgess’s continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Burgess Paul D.
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 802,242 contracts (Direct)
Footnotes (3)
- F1. The options vested and became exercisable as to 25% of the total shares on September 16, 2025 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
- F2. The options vested and became exercisable as to 25% of the total shares on December 9, 2025 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
- F3. The options vest and become exercisable as to 25% of the total shares on November 5, 2026 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Option exercise price: $7.24 per share
Underlying shares at $7.24: 325,491 shares
Option exercise price: $5.25 per share
+5 more
8 metrics
Option exercise price
$7.24 per share
Stock option on common stock expiring November 5, 2035
Underlying shares at $7.24
325,491 shares
Stock option, direct ownership, underlying common stock
Option exercise price
$5.25 per share
Two stock option grants on common stock
Underlying shares at $5.25 (grant 1)
191,444 shares
Stock option expiring December 9, 2034
Underlying shares at $5.25 (grant 2)
285,307 shares
Stock option expiring September 19, 2034
Vesting start date (grant 1)
September 16, 2025
25% vested then 36 monthly installments
Vesting start date (grant 2)
December 9, 2025
25% vested then 36 monthly installments
Future vesting start (grant 3)
November 5, 2026
25% vests then 36 monthly installments
Key Terms
Stock Option (right to buy), exercise price, expiration date, vesting, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "7.2400" and "5.2500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2035-11-05T00:00:00.000Z" and similar"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The options vested and became exercisable as to 25% of the total shares"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
substantially equal monthly installments financial
"thereafter in 36 substantially equal monthly installments"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Paul D. Burgess report owning in Kailera Therapeutics (KLRA) on this Form 3?
Paul D. Burgess reports direct holdings of three stock option grants in Kailera Therapeutics common stock, covering 325,491 shares at $7.24 and 191,444 and 285,307 shares at $5.25, each with long-dated expiration dates in 2034 and 2035.
What are the exercise prices of the Kailera Therapeutics (KLRA) options held by Paul D. Burgess?
Burgess holds stock options with exercise prices of $7.24 per share for 325,491 underlying shares and $5.25 per share for two grants covering 191,444 and 285,307 underlying shares, providing rights to buy Kailera Therapeutics common stock at those fixed prices.
How do the vesting schedules work for Paul D. Burgess’s KLRA stock options?
Two option grants vested 25% on September 16, 2025 and December 9, 2025, respectively, then vest in 36 substantially equal monthly installments. The third grant will vest 25% on November 5, 2026, then continue vesting monthly, all conditioned on his continued service at each vesting date.
When do Paul D. Burgess’s Kailera Therapeutics (KLRA) stock options expire?
The reported stock options have expiration dates of September 19, 2034, December 9, 2034, and November 5, 2035. After these dates, any unexercised options lapse, meaning the right to buy Kailera Therapeutics common shares at the specified exercise prices ends.
Does this Kailera Therapeutics (KLRA) Form 3 show any recent buying or selling by Paul D. Burgess?
The Form 3 lists Burgess’s existing stock option holdings and related vesting schedules but does not report any open-market purchases or sales. It functions as an initial ownership statement, detailing option positions rather than new buy or sell transactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
